SEC Comment Letter for BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149) (BIVI) — Jun 16, 2016
BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149)
Date: June 16, 2016 · CIK: 0001580149 · Accession: 0000000000-16-080778
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4720 June 16, 2016 Jonathan M. Adams Chief Executive Officer NanoAntibiotics, Inc. 100 Cummings Center, Suite 247 -C Beverly, MA 01915 USA
Re: NanoAntibiotics, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 8, 2016 File No. 000 -55292
Dear Mr. Adams:
We have reviewed your filing an d have the following comment . Please respond to th is comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment appl ies to your facts and circumstances, please tell us why in your response.
After revie wing your response to this comment , we may have additional comments.
Proposal 1 – Name Change Amendment, page 7
1. We refer to your proposal to amend your Articles of Incorporation to change your name to BioVie Inc. Please revise your disclosu re to provide a reason for the name change pursuant to Item 19 of Schedule 14A.
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securitie s Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have m ade.
Jonathan M. Adams NanoAntibiotics, Inc. June 16, 2016 Page 2
In responding to our comments, please provide a written statement from the company acknowledging that:
the company is responsible for the adequacy and accuracy of the disclosure in the filing;
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws o f the United States.
Please contact Irene Paik at (202) 551 -6553 or Mary Beth Breslin at (202) 551 -3625 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4720 June 16, 2016 Jonathan M. Adams Chief Executive Officer NanoAntibiotics, Inc. 100 Cummings Center, Suite 247 -C Beverly, MA 01915 USA Re: NanoAntibiotics, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 8, 2016 File No. 000 -55292 Dear Mr. Adams: We have reviewed your filing an d have the following comment . Please respond to th is comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment appl ies to your facts and circumstances, please tell us why in your response. After revie wing your response to this comment , we may have additional comments. Proposal 1 – Name Change Amendment, page 7 1. We refer to your proposal to amend your Articles of Incorporation to change your name to BioVie Inc. Please revise your disclosu re to provide a reason for the name change pursuant to Item 19 of Schedule 14A. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securitie s Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have m ade. Jonathan M. Adams NanoAntibiotics, Inc. June 16, 2016 Page 2 In responding to our comments, please provide a written statement from the company acknowledging that: the company is responsible for the adequacy and accuracy of the disclosure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws o f the United States. Please contact Irene Paik at (202) 551 -6553 or Mary Beth Breslin at (202) 551 -3625 with any questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Peter Campitiello Kane Kessler, P.C.